News

The study was conducted in animal models by researchers at Alexion Pharmaceuticals, the Yale University School of Medicine and the Brigham and Women’s Hospital. Alexion believes the results

This is the second award that Saegis has received from the Stanley Medical Research Institute (SMRI) for this promising therapeutic clinical development program. In January 2004, Saegis received

The parties have already started generating fully human anti-PD-1 antibody product candidates under Ono’s intellectual property regarding PD-1 and using Medarex’s proprietary UltiMAb Human Antibody Development System. They

This study will use a daily dosing schedule with ADH-1 (Exherin) administered Monday through to Friday every three weeks with the aim of defining dose tolerance and anti-tumor

A total of $31 million in private equity has now been conveyed to the company for the purpose of bringing small molecule product candidates into clinical trials. Following

The planned randomized, open-label trial will include approximately 332 newly transplanted kidney patients from clinical trial sites across North America. Isotechnika had previously received a letter from Health

The phase I portion of this multi-center study will determine the dosage, safety and tolerability of talotrexin in refractory leukemia patients, including both myeloid and lymphoid leukemias. The

The small molecule Heat Shock Protein 90 or HSP90 inhibitors have low molecular weights, require few synthetic steps and are derived from a novel chemical scaffold. They exhibit

FAS20013 proved to be powerfully bactericidal against anaerobically adapted mycobacterium bovis BCG, killing the BCG at concentrations ranging from 1.5 micrograms (60% killing activity) to 50 micrograms concentration